Industry News
Outlook Therapeutics Completes 12-Week Analysis of NORSE EIGHT Trial for ONS-5010 in Wet AMD

Outlook Therapeutics has finalized the analysis of 12-week safety and efficacy data from the NORSE E...

read more
Outlook Therapeutics Completes 12-Week Analysis of NORSE EIGHT Trial for ONS-5010 in Wet AMD
January 17, 2025
Prevent Blindness Receives Historic $9.7 Million Legacy Donation

Prevent Blindness, a leading organization dedicated to promoting eye health, announced it has receiv...

read more
Prevent Blindness Receives Historic $9.7 Million Legacy Donation
January 17, 2025
Inflammasome Therapeutics Reports Promising Results from K8 Implant Trial for Geographic Atrophy

Inflammasome Therapeutics has announced encouraging 3-month topline results from a clinical trial ev...

read more
Inflammasome Therapeutics Reports Promising Results from K8 Implant Trial for Geographic Atrophy
January 17, 2025
4DMT Announces Positive Interim Results from SPECTRA Clinical Trial for 4D-150 in Diabetic Macular Edema

4D Molecular Therapeutics (4DMT) has released promising topline interim data from Part 1 of the SPEC...

read more
4DMT Announces Positive Interim Results from SPECTRA Clinical Trial for 4D-150 in Diabetic Macular Edema
January 16, 2025
Ocugen Reports Positive 2-Year Results for OCU400 Gene Therapy in Retinitis Pigmentosa

Ocugen, Inc. has announced encouraging 2-year safety and efficacy results from its Phase 1/2 clinica...

read more
Ocugen Reports Positive 2-Year Results for OCU400 Gene Therapy in Retinitis Pigmentosa
January 16, 2025
AbbVie and Regenxbio Share Updates on ABBV-RGX-314 Gene Therapy for Wet AMD and Diabetic Retinopathy

AbbVie and Regenxbio have announced updates on the clinical development of ABBV-RGX-314, a potential...

read more
AbbVie and Regenxbio Share Updates on ABBV-RGX-314 Gene Therapy for Wet AMD and Diabetic Retinopathy
January 16, 2025
PulseSight Therapeutics Advances PST-611 for Dry AMD/GA with Phase 1 Clinical Plan

PulseSight Therapeutics SAS has submitted a clinical trial authorization (CTA) to the Agence Nationa...

read more
PulseSight Therapeutics Advances PST-611 for Dry AMD/GA with Phase 1 Clinical Plan
January 15, 2025
Sling Therapeutics Announces Positive Results from Phase 2b/3 LIDS Trial of Linsitinib for Thyroid Eye Disease

Sling Therapeutics has revealed positive topline efficacy and safety results from the Phase 2b/3 LID...

read more
Sling Therapeutics Announces Positive Results from Phase 2b/3 LIDS Trial of Linsitinib for Thyroid Eye Disease
January 15, 2025
Samsara Vision Announces Positive 6-Month Outcomes of SING IMT Surgery

Samsara Vision has reported promising intermediate-term visual and safety outcomes for the SING IMT ...

read more
Samsara Vision Announces Positive 6-Month Outcomes of SING IMT Surgery
January 15, 2025
Formycon Partners with Teva and Klinge Biopharma for Commercialization of Aflibercept Biosimilar FYB203 (AHZANTIVE)

Formycon AG, in partnership with Teva Pharmaceuticals International GmbH and Klinge Biopharma GmbH, ...

read more
Formycon Partners with Teva and Klinge Biopharma for Commercialization of Aflibercept Biosimilar FYB203 (AHZANTIVE)
January 14, 2025
More